| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |